-
公开(公告)号：US20240082325A1
公开(公告)日：2024-03-14
申请号：US18510979
申请日：2023-11-16
申请人： BioGaia AB
发明人： Stefan Roos , Wolfgang Kunze , John Bienenstock
IPC分类号： A61K35/747 , A61K35/745 , A61P1/00
CPC分类号： A61K35/747 , A61K35/745 , A61P1/00
摘要： A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.
-
公开(公告)号：US20220168365A1
公开(公告)日：2022-06-02
申请号：US17670968
申请日：2022-02-14
申请人： BIOGAIA AB
发明人： Stefan Roos
IPC分类号： A61K35/747 , C12N1/20
摘要： The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.
-
3.发明申请公开(公告)号：US20230057324A1
公开(公告)日：2023-02-23
申请号：US17251410
申请日：2019-07-24
申请人： BioGaia AB
发明人： Stefan Roos
IPC分类号： A61K35/747 , A61P17/02 , A61K31/7076 , C12N1/20 , C12Q1/44
摘要： The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of adenosine, for use in the production of adenosine in a subject. Therapeutic uses of such strains include the treatment or prevention of diseases associated with adenosine deficiency, for example wound healing. Novel strains are also provided.
-
公开(公告)号：US20220347237A1
公开(公告)日：2022-11-03
申请号：US16961598
申请日：2019-07-24
申请人： BioGaia AB
发明人： Stefan Roos , Bo Möllstam
摘要： The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.
-
公开(公告)号：US11911424B2
公开(公告)日：2024-02-27
申请号：US16961598
申请日：2019-07-24
申请人： BioGaia AB
发明人： Stefan Roos , Bo Möllstam
CPC分类号： A61K35/747 , A61P5/00 , A61P25/28 , C12N1/205 , C12P17/165 , C12P19/40 , C12R2001/225 , C12Y301/03031
摘要： The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.
-
公开(公告)号：US20220354909A1
公开(公告)日：2022-11-10
申请号：US17623543
申请日：2020-11-06
申请人： BIOGAIA AB
发明人： Estelle Grasset , Muhammed Khan , Bo Möllstam , Stefan Roos
IPC分类号： A61K35/747 , C12N1/20 , C12Q1/02 , A61P25/00
摘要： The invention relates to selection of bacterial strain for use in treating serotonin deficiency and/or a disease related to serotonin deficiency by culturing bacteria of a lactic acid producing bacterial strain, under aerobic conditions, in a culture medium comprising tryptophan. Any serotonin produced by the bacteria of the lactic acid producing bacterial strain in the culture medium is detected and the lactic acid producing bacterial strain is selected as effective in treating serotonin deficiency and/or a disease related to serotonin deficiency in a subject if serotonin is detected in the culture medium.
-
公开(公告)号：US11285181B2
公开(公告)日：2022-03-29
申请号：US16496509
申请日：2018-03-27
申请人： BIOGAIA AB
发明人： Stefan Roos
IPC分类号： A61K35/747 , C12N1/20 , A61K35/00 , C12R1/225
摘要： The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.
-
公开(公告)号：US11857582B2
公开(公告)日：2024-01-02
申请号：US17045315
申请日：2020-04-17
申请人： BioGaia AB
发明人： Stefan Roos , Wolfgang Kunze , John Bienenstock
IPC分类号： A61K35/747 , A61P1/00 , A61K35/745
CPC分类号： A61K35/747 , A61K35/745 , A61P1/00
摘要： A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.
-
公开(公告)号：US11730780B2
公开(公告)日：2023-08-22
申请号：US17670968
申请日：2022-02-14
申请人： BIOGAIA AB
发明人： Stefan Roos
IPC分类号： A61K35/747 , C12N1/20 , A61K35/00 , C12R1/225
CPC分类号： A61K35/747 , C12N1/205 , A61K2035/115 , C12R2001/225
摘要： The present invention relates to novel strains of lactic acid bacteria, more specifically, novel strains of Lactobacillus reuteri, capable of utilizing ethanolamine. This characteristic makes it possible for the bacteria to compete for the same substrate as pathogenic ethanolamine-utilizing pathogens, thereby presenting an effective means to combat infections resulting from such pathogenic bacteria. There is also provided a method of selecting further ethanolamine-utilizing lactic acid bacteria, as well as other methods and uses involving said novel strains and other ethanolamine-utilizing lactic acid bacteria.
-
公开(公告)号：US20240216447A1
公开(公告)日：2024-07-04
申请号：US18416049
申请日：2024-01-18
申请人： BioGaia AB
发明人： Stefan Roos , Bo Möllstam
CPC分类号： A61K35/747 , A61P5/00 , A61P25/28 , C12N1/205 , C12P17/165 , C12P19/40 , C12R2001/225 , C12Y301/03031
摘要： The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.015 秒)
